News Merck shows canny cancer strategy in $5.76bn Eisai milestone... Firms will co-develop Lenvima and Keytruda combinations
News Eisai disappointed after NICE rejects earlier use for breast... NICE says no to Halaven in second line breast cancer
News NICE recommends funding for three thyroid cancer drugs Eisai's drug finally funded after two year delay
News NICE recommends Eisai's kidney cancer combination NICE has recommended Eisai’s Kisplyx (lenvatinib) in combination with Novartis’ Afinitor (everolimus) in kidney cancer after the company further dropped its price.
News Eisai: UK gives pharma a poor deal, may invest elsewhere Japanese pharma getting frustrated with NICE
News NICE rejects Eisai's Halaven in new breast cancer use NICE rejects drug after finding gap in clinical data
News Immunovant's thyroid eye disease drug flunks pivotal trials Immunovant shares were sliding today after it reported that FcRn blocker batoclimab failed a pair of phase 3 trials in thyroid eye disease.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
